From the data currently available, it would seem that Nmnat2 manipulation, IGF signaling modulation and cellular autophagy targeting may be useful in targeting SIRT6 for future drugs in order to treat cardiac hypertrophy. This evidence concerns the gene IGF1 and cardiac hypertrophy.